Commentary
Video
Advances in Minimally Invasive Diagnostic Tests for Neurodegenerative Diseases: David Shprecher, DO, MSci, FAAN
The director of movement disorders at the Banner Sun Health Research Institute talked about making strides in developing minimally invasive tests and imaging ligands for neurodegenerative diseases, such as Parkinson disease. [WATCH TIME: 2 minutes]
WATCH TIME: 2 minutes
"I think we really would like to see tests that are minimally invasive, that could be therefore more broadly available and broadly utilized."
Prior studies have shown that distinguishing patients with atypical parkinsonisms from those with idiopathic Parkinson disease (PD) can be a significant challenge for clinicians because of the similar symptoms presented in the diseases. For instance, progressive supranuclear palsy (PSP) and corticobasal degeneration can exhibit similar pathological features and encompass various phenotypic variants.1 Additionally, previous research indicated that incorrect treatment provides limited benefit to patients, complicates care needs, and increases the patient burden. Consequently, it is important for providers to make accurate diagnoses, as this can determine the most effective treatment and management strategies.
David Shprecher, DO, MSci, FAAN, recently presented a talk on diagnostic pearls in atypical parkinsonism at the 3rd Annual Advanced Therapeutics in Movement and Related Disorders (ATMRD) Congress, held by the PMD Alliance from June 22-25, 2024. During his presentation, he discussed how providers could differentiate the similar clinical and pathological features of atypical parkinsonian syndromes from idiopathic PD. Moreover, in the talk, Shprecher spoke about how to recognize important features that may indicate red flags for atypical parkinsonism and reviewed the latest advancements for diagnostic and treatments that are currently available.
Shprecher, director of movement disorders at the Banner Sun Health Research Institute, sat down with NeurologyLive® at the Congress to discuss the potential benefits of developing minimally invasive tests for neurodegenerative diseases. Shprecher, who also serves as a clinical associate professor at University of Arizona-Phoenix, spoke about how synuclein imaging ligands can improve the diagnosis of synucleinopathies. Furthermore, he talked about the implications of developing tau ligands for diseases other than Alzheimer disease, such as PSP.
Click here for more coverage of ATMRD 2024.
